These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 17463024)

  • 21. Using the BioAssay Ontology for analyzing high-throughput screening data.
    Zander Balderud L; Murray D; Larsson N; Vempati U; Schürer SC; Bjäreland M; Engkvist O
    J Biomol Screen; 2015 Mar; 20(3):402-15. PubMed ID: 25512330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HTS technologies in biopharmaceutical discovery.
    Wu G; Doberstein SK
    Drug Discov Today; 2006 Aug; 11(15-16):718-24. PubMed ID: 16846799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of high-field asymmetric waveform ion mobility spectrometry coupled to nanoelectrospray ionization for bioanalysis in drug discovery.
    Hatsis P; Brockman AH; Wu JT
    Rapid Commun Mass Spectrom; 2007; 21(14):2295-300. PubMed ID: 17577878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interpretation of uniform-well readouts.
    Josiah S
    Methods Mol Biol; 2009; 486():177-92. PubMed ID: 19347624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and implementation of high-throughput screening assays.
    Macarrón R; Hertzberg RP
    Methods Mol Biol; 2009; 565():1-32. PubMed ID: 19551355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial compound selection for sequential screening.
    Young SS; Lam RL; Welch WJ
    Curr Opin Drug Discov Devel; 2002 May; 5(3):422-7. PubMed ID: 12058618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian versus Frequentist statistical modeling: a debate for hit selection from HTS campaigns.
    Cloutier LM; Sirois S
    Drug Discov Today; 2008 Jun; 13(11-12):536-42. PubMed ID: 18549981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of diversity-based, high-throughput screening on drug discovery: "chance favours the prepared mind".
    Snowden M; Green DV
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):553-8. PubMed ID: 18600571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic error detection in experimental high-throughput screening.
    Dragiev P; Nadon R; Makarenkov V
    BMC Bioinformatics; 2011 Jan; 12():25. PubMed ID: 21247425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adopting a practical statistical approach for evaluating assay agreement in drug discovery.
    Sun D; Whitty A; Papadatos J; Newman M; Donnelly J; Bowes S; Josiah S
    J Biomol Screen; 2005 Aug; 10(5):508-16. PubMed ID: 16093560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction: cell-based assays for high-throughput screening.
    An WF; Tolliday NJ
    Methods Mol Biol; 2009; 486():1-12. PubMed ID: 19347612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a new drug--from target identification to ultra-high-throughput screening.
    Golz S; Hüser J
    Clin Lab; 2007; 53(1-2):77-9. PubMed ID: 17323829
    [No Abstract]   [Full Text] [Related]  

  • 33. Assay concordance between SPA and TR-FRET in high-throughput screening.
    von Ahsen O; Schmidt A; Klotz M; Parczyk K
    J Biomol Screen; 2006 Sep; 11(6):606-16. PubMed ID: 16760369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of high throughput screening in the early stage of drug research].
    Keserü GM
    Acta Pharm Hung; 2004; 74(1):5-10. PubMed ID: 15524043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Process validation and screen reproducibility in high-throughput screening.
    Coma I; Clark L; Diez E; Harper G; Herranz J; Hofmann G; Lennon M; Richmond N; Valmaseda M; Macarron R
    J Biomol Screen; 2009 Jan; 14(1):66-76. PubMed ID: 19171922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-throughput assays for promiscuous inhibitors.
    Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK
    Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Image-based chemical screening.
    Carpenter AE
    Nat Chem Biol; 2007 Aug; 3(8):461-5. PubMed ID: 17637778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of mixture distributions to deconvolute the behavior of "hits" and controls in high-throughput screening data.
    Buxser S; Chapman DL
    Anal Biochem; 2007 Feb; 361(2):197-209. PubMed ID: 17214952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fragment-based activity space: smaller is better.
    Hesterkamp T; Whittaker M
    Curr Opin Chem Biol; 2008 Jun; 12(3):260-8. PubMed ID: 18316043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental design and statistical methods for improved hit detection in high-throughput screening.
    Malo N; Hanley JA; Carlile G; Liu J; Pelletier J; Thomas D; Nadon R
    J Biomol Screen; 2010 Sep; 15(8):990-1000. PubMed ID: 20817887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.